Literature DB >> 28671324

Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial.

Lynne Uhl1,2, Joseph E Kiss3, Elizabeth Malynn1, Deirdra R Terrell4, Sara K Vesely4, James N George4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28671324     DOI： 10.1111/trf.14193

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  5 in total

Review 1.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

2.  Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.

Authors:  Hanny Al-Samkari; Rachael F Grace; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

3.  Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Amit Gokhale; Jeanne E Hendrickson; Christopher Tormey; Alfred Ian Lee
Journal:  Blood Adv       Date:  2020-02-11

Review 4.  Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Muhammad Haisum Maqsood; Kinza Rubab; Muhammad Zaigham Maqsood
Journal:  Cureus       Date:  2019-07-29

Review 5.  IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies.

Authors:  Inga Koneczny; John Tzartos; Marina Mané-Damas; Vuslat Yilmaz; Maartje G Huijbers; Konstantinos Lazaridis; Romana Höftberger; Erdem Tüzün; Pilar Martinez-Martinez; Socrates Tzartos; Frank Leypoldt
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.